Literature DB >> 18650261

A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression.

Carolyn L Buller1, Robert D Loberg, Ming-Hui Fan, Qihong Zhu, James L Park, Eileen Vesely, Ken Inoki, Kun-Liang Guan, Frank C Brosius.   

Abstract

Glucose transport is a highly regulated process and is dependent on a variety of signaling events. Glycogen synthase kinase-3 (GSK-3) has been implicated in various aspects of the regulation of glucose transport, but the mechanisms by which GSK-3 activity affects glucose uptake have not been well defined. We report that basal glycogen synthase kinase-3 (GSK-3) activity regulates glucose transport in several cell types. Chronic inhibition of basal GSK-3 activity (8-24 h) in several cell types, including vascular smooth muscle cells, resulted in an approximately twofold increase in glucose uptake due to a similar increase in protein expression of the facilitative glucose transporter 1 (GLUT1). Conversely, expression of a constitutively active form of GSK-3beta resulted in at least a twofold decrease in GLUT1 expression and glucose uptake. Since GSK-3 can inhibit mammalian target of rapamycin (mTOR) signaling via phosphorylation of the tuberous sclerosis complex subunit 2 (TSC2) tumor suppressor, we investigated whether chronic GSK-3 effects on glucose uptake and GLUT1 expression depended on TSC2 phosphorylation and TSC inhibition of mTOR. We found that absence of functional TSC2 resulted in a 1.5-to 3-fold increase in glucose uptake and GLUT1 expression in multiple cell types. These increases in glucose uptake and GLUT1 levels were prevented by inhibition of mTOR with rapamycin. GSK-3 inhibition had no effect on glucose uptake or GLUT1 expression in TSC2 mutant cells, indicating that GSK-3 effects on GLUT1 and glucose uptake were mediated by a TSC2/mTOR-dependent pathway. The effect of GSK-3 inhibition on GLUT1 expression and glucose uptake was restored in TSC2 mutant cells by transfection of a wild-type TSC2 vector, but not by a TSC2 construct with mutated GSK-3 phosphorylation sites. Thus, TSC2 and rapamycin-sensitive mTOR function downstream of GSK-3 to modulate effects of GSK-3 on glucose uptake and GLUT1 expression. GSK-3 therefore suppresses glucose uptake via TSC2 and mTOR and may serve to match energy substrate utilization to cellular growth.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18650261      PMCID: PMC2544442          DOI: 10.1152/ajpcell.00554.2007

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  45 in total

1.  Mind the GAP: Wnt steps onto the mTORC1 train.

Authors:  Andrew Y Choo; Philippe P Roux; John Blenis
Journal:  Cell       Date:  2006-09-08       Impact factor: 41.582

2.  Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

Authors:  D D Sarbassov; David A Guertin; Siraj M Ali; David M Sabatini
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

3.  Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice.

Authors:  Masayoshi Sakaguchi; Motohide Isono; Keiji Isshiki; Toshiro Sugimoto; Daisuke Koya; Atsunori Kashiwagi
Journal:  Biochem Biophys Res Commun       Date:  2005-12-12       Impact factor: 3.575

4.  TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth.

Authors:  Ken Inoki; Hongjiao Ouyang; Tianqing Zhu; Charlotta Lindvall; Yian Wang; Xiaojie Zhang; Qian Yang; Christina Bennett; Yuko Harada; Kryn Stankunas; Cun-Yu Wang; Xi He; Ormond A MacDougald; Ming You; Bart O Williams; Kun-Liang Guan
Journal:  Cell       Date:  2006-09-08       Impact factor: 41.582

5.  Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking.

Authors:  Heather L Wieman; Jessica A Wofford; Jeffrey C Rathmell
Journal:  Mol Biol Cell       Date:  2007-02-14       Impact factor: 4.138

Review 6.  Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer.

Authors:  Maria L Macheda; Suzanne Rogers; James D Best
Journal:  J Cell Physiol       Date:  2005-03       Impact factor: 6.384

Review 7.  TSC2: filling the GAP in the mTOR signaling pathway.

Authors:  Yong Li; Michael N Corradetti; Ken Inoki; Kun-Liang Guan
Journal:  Trends Biochem Sci       Date:  2004-01       Impact factor: 13.807

Review 8.  Role for GLUT1 in diabetic glomerulosclerosis.

Authors:  Charles W Heilig; Frank C Brosius; Carol Cunningham
Journal:  Expert Rev Mol Med       Date:  2006-02-06       Impact factor: 5.600

9.  Suppression of tumorigenicity by the wild-type tuberous sclerosis 2 (Tsc2) gene and its C-terminal region.

Authors:  F Jin; R Wienecke; G H Xiao; J C Maize; J E DeClue; R S Yeung
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

10.  Modeling, docking, and simulation of the major facilitator superfamily.

Authors:  John Holyoake; Victoria Caulfeild; Stephen A Baldwin; Mark S P Sansom
Journal:  Biophys J       Date:  2006-09-15       Impact factor: 4.033

View more
  103 in total

1.  Distinct growth hormone receptor signaling modes regulate skeletal muscle development and insulin sensitivity in mice.

Authors:  Mahendra D Mavalli; Douglas J DiGirolamo; Yong Fan; Ryan C Riddle; Kenneth S Campbell; Thomas van Groen; Stuart J Frank; Mark A Sperling; Karyn A Esser; Marcas M Bamman; Thomas L Clemens
Journal:  J Clin Invest       Date:  2010-11       Impact factor: 14.808

Review 2.  Metabolic benefits of resistance training and fast glycolytic skeletal muscle.

Authors:  Nathan K LeBrasseur; Kenneth Walsh; Zoltan Arany
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-11-02       Impact factor: 4.310

Review 3.  Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease.

Authors:  Dimitrios Kapogiannis; Mark P Mattson
Journal:  Lancet Neurol       Date:  2010-12-10       Impact factor: 44.182

4.  Stimulation of glucose transport in osteoblastic cells by parathyroid hormone and insulin-like growth factor I.

Authors:  E Zoidis; C Ghirlanda-Keller; C Schmid
Journal:  Mol Cell Biochem       Date:  2010-11-13       Impact factor: 3.396

5.  Restoring glucose uptake rescues neutrophil dysfunction and protects against systemic fungal infection in mouse models of kidney disease.

Authors:  Chetan V Jawale; Kritika Ramani; De-Dong Li; Bianca M Coleman; Rohan S Oberoi; Saran Kupul; Li Lin; Jigar V Desai; Greg M Delgoffe; Michail S Lionakis; Filitsa H Bender; Alexander J Prokopienko; Thomas D Nolin; Sarah L Gaffen; Partha S Biswas
Journal:  Sci Transl Med       Date:  2020-06-17       Impact factor: 17.956

6.  Inhibition of GSK-3 induces differentiation and impaired glucose metabolism in renal cancer.

Authors:  Krishnendu Pal; Ying Cao; Irina N Gaisina; Santanu Bhattacharya; Shamit K Dutta; Enfeng Wang; Hendra Gunosewoyo; Alan P Kozikowski; Daniel D Billadeau; Debabrata Mukhopadhyay
Journal:  Mol Cancer Ther       Date:  2013-12-10       Impact factor: 6.261

7.  Insulin receptor substrate 2-mediated phosphatidylinositol 3-kinase signaling selectively inhibits glycogen synthase kinase 3β to regulate aerobic glycolysis.

Authors:  Justine Landis; Leslie M Shaw
Journal:  J Biol Chem       Date:  2014-05-08       Impact factor: 5.157

8.  Diet-induced weight loss leads to a switch in gene regulatory network control in the rectal mucosa.

Authors:  Ashley J Vargas; John Quackenbush; Kimberly Glass
Journal:  Genomics       Date:  2016-08-11       Impact factor: 5.736

9.  Cardioprotection by resveratrol: a novel mechanism via autophagy involving the mTORC2 pathway.

Authors:  Narasimman Gurusamy; Istvan Lekli; Subhendu Mukherjee; Diptarka Ray; Md Kaimul Ahsan; Mihaela Gherghiceanu; Lawrence M Popescu; Dipak K Das
Journal:  Cardiovasc Res       Date:  2009-12-03       Impact factor: 10.787

10.  20-HETE attenuates the response of glucose-stimulated insulin secretion through the AKT/GSK-3β/Glut2 pathway.

Authors:  Bijun Zhang; Guangrui Lai; Jingjing Wu; Ru Sun; Runhong Xu; Xianghong Yang; Yafei Qi; Yanyan Zhao
Journal:  Endocrine       Date:  2016-08-27       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.